Rituximab use in pediatric central demyelinating disease

Pediatric Neurology

Volumn 51, Issue 1, 2014, Pages 114-118

  Beres, Shannon J ^a   Graves, Jennifer ^a   Waubant, Emmanuelle ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

demyelinating diseases; devic disease; multiple sclerosis; neuromyelitis optica; rituximab; treatment

Indexed keywords

BETA1A INTERFERON; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; PARACETAMOL; RITUXIMAB; STEROID; ANTIBODY; AQP4 PROTEIN, HUMAN; AQUAPORIN 4; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADOLESCENT; ARTICLE; BACKACHE; CENTRAL NERVOUS SYSTEM; CHILD; CHILDHOOD DISEASE; CHILL; CLINICAL ARTICLE; DEMYELINATING DISEASE; DIARRHEA; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HUMAN; INFUSION RELATED REACTION; LABORATORY TEST; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NAUSEA; NEUTROPENIA; PATIENT MONITORING; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; STEROID THERAPY; SWELLING; TACHYCARDIA; TACHYPNEA; TREATMENT DURATION; UNITED STATES; BLOOD; DEMYELINATING AUTOIMMUNE DISEASES, CNS; IMMUNOLOGY; PRESCHOOL CHILD; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ANTIBODIES; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AQUAPORIN 4; CHILD; CHILD, PRESCHOOL; DEMYELINATING AUTOIMMUNE DISEASES, CNS; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84902500189     PISSN: 08878994     EISSN: 18735150     Source Type: Journal    
DOI: 10.1016/j.pediatrneurol.2014.02.007     Document Type: Article

References (15)

1. V.A. Lennon, T.J. Kryzer, and S.J. Pittock et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel J Exp Med 202 2005 473 477
2. M. Duddy, M. Niino, and F. Adatia et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis J Immunol 178 2007 6092 6099
3. S.H. Kim, S.Y. Huh, S.J. Lee, A. Joung, and H.J. Kim A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder JAMA Neurology 70 2013 1110 1117
4. A. Jacob, B.G. Weinshenker, and I. Violich et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients Arch Neurol 65 2008 1443 1448
5. G.S. Bedi, A.D. Brown, S.R. Delgado, N. Usmani, B.L. Lam, and W.A. Sheremata Impact of rituximab on relapse rate and disability in neuromyelitis optica Mult Scler 17 2011 1225 1230
6. H.L. Pellkofer, M. Krumbholz, and A. Berthele et al. Long term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab Neurology 76 2011 1310 1315
7. S.L. Hauser, E. Waubant, and D.L. Arnold et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis N Engl J Med 358 2008 676 688
8. A. Bar-Or, P.A. Calabresi, and D. Arnold et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial Ann Neurol 63 2008 395 400
9. R.T. Naismith, L. Picco, and J.A. Lyons et al. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial Neurology 74 2010 1860 1867
10. N.A. Mahmood, K. Silver, K. Onel, M. Ko, and A. Javed Efficacy and safety of rituximab in pediatric neuromyelitis optica J Child Neurol 26 2011 244 247
11. A. McKeon, V.A. Lennon, and T. Lotze et al. CNS aquaporin-4 autoimmunity in children Neurology 71 2008 93 100
12. L.B. Krupp, M. Tardieu, and M.P. Amato et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions Mult Scler 19 2013 1261 1267
13. J.C. Edwards, L. Szczepanski, and J. Szechinski et al. Efficacy of B-cell targeted therapy with rituximab in patients with rheumatoid arthritis N Engl J Med 350 2004 2572 2581
14. K. Dunleavy, K. Tay, and W.H. Wilson Rituximab-associated neutropenia Semin Hematol 47 2010 180 186
15. E. Keystone, R. Fleischmann, and P. Emery et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis Arthritis Rheum 56 2007 3896 3908